Innovative output and firm size in the pharmaceutical industry

Abstract Numerous studies have examined the validity of Schumpeter's hypothesis that innovative output increases with firm size. Nonetheless, conclusive acceptance or rejection of the hypothesis has not been possible. The pharmaceutical industry, in particular, provides conflicting evidence. Using a new set of data for that industry, our study leads to a conclusion that diseconomies of sale exist for R&D in the pharmaceutical industry.